Dyadic International, Inc.

Good evening, and welcome to Dyadic International's year-end 2024 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference call is being recorded as of today, March 26, 2025. I would now like to turn the call over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.

Thank you. Good evening and welcome everyone to Dyadic International's full year 2024 conference call. I hope you have had a chance to review Dyadic's press releases announcing financial results for fiscal year ended December 31st, 2024. You may access our press release on Form 10-K under the investor session of the company's website at dyadic.com. On today's call, our president and CEO, Mark Emelfarb, and our chief operating officer, Joe Hazleton, will give a review of our 2024 business and corporate highlights and provide a commentary on the strategic direction of the business. I will follow with a review of our financial results in more detail. We'll then hold a brief question and answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause DADIC's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. DADIC expressly disclaims any duty to provide updates to its forward-looking statements. whether because of new information, future events, or otherwise. Participants are directed to the risk factors set forth in DIATIC's report filed with the FCC. It is now my pleasure to pass the call to our CEO, Mark Imhoff. Mark?

Thank you, Ping. Welcome, everyone, and thank you for joining DIATIC's full-year 2024 conference call. We're excited to share how our strategic focus on near-term product commercialization and technology licensing has positioned Dyadic to capitalize on the current and emerging opportunities. In 2024, we delivered strong revenue performance, including $1.9 million in milestone and license payments, driven by our emphasis on products that do not require human or animal clinical trials for commercialization. These results reflect our commitment to unlocking the full potential of our proprietary C1-Adapavis microbial protein production platforms. These platforms are enabling us to generate immediate revenue through high-value alternative protein applications, including recombinant human albumin, transferrin, TNase-1, and alpha-lactalbumin. At the same time, we're advancing mid- and long-term opportunities in human and animal health by applying our platforms to develop antigens, antibodies, enzymes, and other proteins that address critical needs in life sciences, food and nutrition, and bioindustrial markets. Our dual-track strategy, commercializing near-term, non-pharmaceutical products while building a robust biopharmaceutical pipeline, continues to drive value. We are strengthening our global impact through partnerships with academia, industry, government, and leading nonprofit and public health organizations. We're proud to be working with the Coalition for Epidemic Preparedness Initiative, CEPI, Foundation Biotech Napola de Siena, and the Gates Foundation, and a growing number of other collaborators to accelerate the development and adoption of our C1 platform for vaccines and treatments, supporting global health preparedness and access to affordable biologics. As we move forward, DIAC remains deeply committed to delivering sustainable value to our shareholders and partners. With a growing pipeline, a strong network of collaborators, and platforms built for efficiency and scalability, we are well positioned to lead in the global production of enzymes, alternative proteins, and biopharmaceuticals, meeting the demands of today and shaping the solutions of tomorrow. I would now like to turn the call over to our TBI operating officer, Joe Hazleton, to provide an update on business results for 2024.